The introduction of ticagrelor, one of the first directly-acting oral antiplatelet drugs, provided
new possibilities in the prevention of thrombotic events in patients with acute coronary …

Ever since evidence about the increased risk of stent thrombosis with drug eluting stents
(DES) surfaced in 2005, the Food and Drug Administration (FDA) has recommended the use …

Objective To report a case of rhabdomyolysis possibly caused by interaction of ticagrelor
with high-dose atorvastatin. Summary A 62-year-old woman originally from India underwent …

Objective: Unusual clinical course Background: Following acute coronary intervention in
cardiology patients, the combined medical therapy with the platelet inhibitory drug ticagrelor …

Up to the beginning of 2018, a total of eight cases describing rare but clinically important
drug interactions between rosuvastatin and ticagrelor which resulted in rhabdomyolysis …

Atorvastatin and ticagrelor combination is a widely accepted therapy for secondary
prevention of ischaemic heart disease. However, rhabdomyolysis is a well‐known rare side …

We present 3 patients diagnosed with rhabdomyolysis 1–6 months after the initiation of
concomitant rosuvastatin and ticagrelor medication. A literature review and Food and Drug …

Renal function deterioration is a rather frequent side effect of ticagrelor; this is especially so
in patients over the age of 75, with pre-existent mild renal failure and/or taking an …

Context: Much emphasis has been placed on a ticagrelor-aspirin (ASA) interaction in the
Platelet Inhibition and Patient Outcomes (PLATO) trial, despite this particular interaction …

Ticagrelor is more effective than clopidogrel in the prevention of myocardial infarction and
death after acute coronary syndrome (ACS)[1]. However, dyspnea is a relatively frequent …